Análisis

Taejeon Group has signed an exclusive distribution agreement with US health‑supplement brand Metagenics, aiming to launch its products to Korean pharmacists, healthcare professionals and consumers.

Polident introduced a dedicated 5‑minute cleaning solution for orthodontic appliance wearers, addressing low usage despite rising demand.

RF Bio participated in the inaugural AMWC KOREA 2026 in Seoul, presenting its key aesthetic products to international experts and reinforcing its global market position.

WiseBuzz announced the creation of a dedicated US Direct‑to‑Consumer advertising team to help Korean pharma and biotech firms launch DTC campaigns in the United States.

Regalon 140 mg capsules, a newly listed epilepsy drug, saw 32,812 arrival‑notification requests in June, prompting limited shipments and pharmacy delays.

Albozen Korea unveiled a 2026 advertising campaign for its leading oral contraceptive ‘머시론’, highlighting the ‘추구미’ lifestyle trend among modern women.

Celltrion’s biosimilar 베그젤마 (bevacizumab) has been listed in Express Scripts and Optum formularies, strengthening its US oncology market foothold.

June data from Baro Pharm’s BRP Connect shows a sharp change in out‑of‑stock alerts, with ‘레가론캡슐140’ topping the list and epilepsy and combo hypertension medicines rising.

JBK Lab’s CellMed, a pharmacist‑led nutrition counseling brand launched in 2019, now serves over 3,000 member pharmacies nationwide amid shifting market dynamics.

Denmark’s QuantumCell will invest up to $2.2 billion to license AlzeCure’s NeuroRestore platform and lead candidate ACD856, paying $12 million upfront, including a $5 million equity stake.

Rixiana (edoxaban) shows signs of supply pressure across all dosages as its Korean patent expires in November, prompting close monitoring of the market.

Korean Aebot and Samjin Pharma have sharply increased the supply price of the pediatric and adult antidiarrheal Hydrasexan due to raw‑material costs and exchange‑rate shifts.